SG/CALL/MODERNA/180/0.1/17.01.25 | Delayed Deutsche Boerse AG 14:09:53 2024-05-09 EDT | ||
| 0.67 EUR | +6.35% |
|
| Current month | +21.15% | ||
| 1 month | +43.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 0.67 | +6.35% | 0 |
| 24-05-08 | 0.63 | +6.78% | 0 |
| 24-05-07 | 0.59 | -7.81% | 0 |
| 24-05-06 | 0.64 | -13.51% | 0 |
| 24-05-03 | 0.74 | -9.76% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 09, 2024 at 02:09 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SQ860U |
| ISIN | DE000SQ860U6 |
| Date issued | 2023-02-16 |
| Strike | 180 $ |
| Maturity | 2025-01-17 (253 Days) |
| Parity | 10 : 1 |
| Emission price | 5.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.36 € |
|---|---|
| Lowest since issue | 0.21 € |
| Spread | 0.01 € |
| Spread % | 1.49% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
121.9
USD
Average target price
138.7
USD
Spread / Average Target
+13.77%
- Stock Market
- Warrants
- Warrant